Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 8/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482770 | 0.79 | BRD4 (0.42) | BRD4 | |
| SCHEMBL482604 | 0.79 | NSD2 (0.43) | NSD2BCHE | |
| SCHEMBL482712 | 0.76 | ALOX5 (0.39) | — | |
| SCHEMBL482744 | 0.75 | BRD4 (0.42) | BRD4 | |
| SCHEMBL482408 | 0.70 | BRD4 (0.52) | BRD4 | |
| SCHEMBL482411 | 0.70 | BRD4 (0.52) | BRD4 | |
| SCHEMBL482835 | 0.63 | SMN1; SMN2 (0.38) | BRD4TSHRSMN1; SMN2 | |
| SCHEMBL2576017 | 0.62 | BCHE (0.55) | BCHE | |
| SCHEMBL222033 | 0.62 | PTGDR2 (0.54) | BRD4CACNA1GCACNA1HCACNA1ITSHR | |
| SCHEMBL225464 | 0.62 | PTGDR2 (0.54) | BRD4CACNA1GCACNA1HCACNA1ITSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | NSD2 455/4885BCHE 4197/4885BRD4 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.